Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism

In ‘Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism,’ our panel explores how clinicians balance sustained cortisol control with the need to manage long-term metabolic risk in patients with hypercortisolism. The expert faculty discuss the importance of avoiding both undertreatment, which may prolong exposure to cortisol excess, and overtreatment, which may increase the risk of adrenal insufficiency and reduce treatment adherence.

Throughout the discussion, the panelists emphasize that long-term disease control requires attention to both biochemical and clinical outcomes. They discuss the importance of monitoring cortisol control while also aggressively managing comorbidities such as hypertension, diabetes, bone disease, and thromboembolic risk. The panel highlights that even after remission, patients may require continued management of residual metabolic complications and long-term follow-up to assess recovery and prevent further morbidity.

The conversation also examines the complexity of monitoring patients receiving different types of medical therapy. Faculty members explain how monitoring strategies may vary depending on whether a patient is treated with a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor. They discuss the role of urinary free cortisol, late-night salivary cortisol, morning cortisol, ACTH, clinical symptoms, and comorbidity trends in guiding treatment decisions.

The panel of experts further explores how resource availability, patient factors, and test reliability can influence monitoring approaches in real-world practice. They emphasize that no single strategy applies to every patient and that management must be individualized based on disease severity, treatment response, tolerability, and long-term goals. By sharing clinical experience, the faculty provide practical guidance for achieving durable disease control while minimizing metabolic risk.

Our next episode, ‘Management Strategies for Hypercortisolism,’ explores how expert faculty balance cortisol control with treatment-related risks, optimize long-term disease management, and monitor for recurrence. The panelists also discuss patient education, multidisciplinary collaboration, and practical approaches to improving outcomes in individuals with hypercortisolism.